Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): preparation and characterization.

Low molecular weight protamine (LMWP) appears to be a promising solution for heparin neutralization without the protamine-associated catastrophic toxic effects. The feasibility of this hypothesis was proven previously by using a peptide mixture produced from proteolytic digestion of protamine. To further examine the utility of this compound as an ultimate nontoxic protamine substitute, detailed studies on the purification and characterization of LMWP including the precise amino acid sequence, structure-function relationship, and possible mechanism were conducted. A number of LWMP fragments, composed of highly cationic peptides with molecular weights ranging from 700 to 1900 d, were prepared by digestion of native protamine with the protease thermolysin. These fragments were fractionated using a heparin affinity chromatography, and their relative binding strengths toward heparin were elucidated. Five distinct fractions were eluted at NaCl concentration ranging from 0.4 to 1.0 M and were denoted as TDSP1 to TDSP5, in increasing order of eluting ionic strength. Among these 5 fractions, TDSP4 and TDSP5 contained 3 LMWP peptide fragments, and they were found to retain the complete heparin-neutralizing function of protamine. By using a peptide mass spectrometry (MS) fingerprint mapping technique, the amino acid sequences of the microheterogeneous LMWP fragments in all these 5 elution fractions were readily identified. A typical structural scaffold made by arginine clusters in the middle and nonarginine residues at the N-terminal of the peptide sequence was observed for all these LMWP fragments. By aligning the sequences with the potency in heparin neutralization of these LMWP fragments, it was found that retention of potency similar to that of protamine required the presence of at least 2 arginine clusters in the LMWP fragments; such as the sequence of VSRRRRRRGGRRRR seen in the most potent LMWP fraction-TDSP5. The above finding was further validated by using a synthetic LMWP analogue-CRRRRRRR-and it was found that its heparin-neutralizing ability was increased by changing from a monomeric to a dimeric structure of this analogue peptide. Based on these results, the structural requirement for a compound to function as an effective heparin antidote and the possible mechanism involved in heparin neutralization were established.

Antiheparin activity in human endothelial cells.

Human endothelial cells possess antiheparin activity that neutralizes the anticoagulant action of heparin as measured by different tests of the clotting system. The antiheparin activity appears to be associated with an acid-soluble basic protein present in the particulate fraction of the endothelial cell cytoplasm. This finding might have some relevance in the maintenance of hemostasis. Furthermore, it might also have a pharmacological role in terms of resistance to exogenously infused heparin in patients with thromboembolic disorders.

Detection and partial purification of a natural heparin inhibitor from hog small intestine.

A natural occurring heparin inhibitor was detected and was partially purified from the mucosa of hog small intestine. The mucosa was homogenized and was extracted overnight in 0.15 M NaCl, 0.01 M imidazole, 0.001 M EDTA, pH 6.5. When the extract was made to 85% saturation in ammonium sulfate, a large quantity of heparin neutralizing activity was detected in the precipitate. Each small intestine contains approximately 35,000 units of heparin neutralizing activity. This heparin inhibitor was further purified by the procedures of zinc sulfate precipitation, ammonium sulfate fractionation, ethanol precipitaiton and heparin-sepharose chromatography. A 37 fold partial purification with 15% overall recovery was achieved to yield heparin inhibitor with specific activity of 50-65 units per mg of protein.

[Antiheparin immunoglobulin in malignant lymphoma with hypertriglyceridemia, in the hamster]. / Une immunoglobuline anti-héparine chez le hamster hypertriglycéridémique porteur d'un lymphome malin

A massive hypertriglyceridemia associated with low post heparin lipolytic activity, was demonstrated during the growth of a transplanted lymphoma in Hamsters. An immunoglobulin, with high anti-heparin activity, was extracted from the tumor. It could inhibit both the anti-thrombin and prolipase activity of heparin. The role of this anti-heparin immunoglobulin in triglyceride metabolism allows us to consider the hypertriglyceridemia of lymphoma-bearing Hamsters as one of the two previously described types of auto-immune hyperlipidemia.